Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 11;9(2):19. doi: 10.1038/s41408-019-0173-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a The IMiD-resistant cell line, XG1LenRes, was analyzed by MTT assay after co-treatment with lenalidomide and the indicated doses of SGC-CBP30. The response to lenalidomide was substantially restored after SGC-CBP30 was added. b Immunoblotting assays detected the changes of IRF4, MYC, and STAT3 after treatment with either lenalidomide and SGC-CBP30 (S, 0.2 and 0.4 μM) alone or combination (day 3). c SGC-CBP30 treatment also reduced IL6 levels in the culture media of XG1LenRes at day 2 after treatment (by ELISA assay). d–f The IMiD-resistant HMCLs (JJN3, MM.1SLenRes, and KMS11LenRes) were analyzed by MTT assay at day 5 after co-treatment with lenalidomide (10 μm) and the indicated doses of SGC-CBP30. g Immunoblotting analysis was performed at 24 h after co-treatment of KMS11LenRes with Lenalidomide (10 μm) and SGC-CBP30 (S1: 0.5 μM and S2: 0.625 μM)